Myeloid cells constitute a fundamental part of the innate immune system, including many subsets with diverse functions. One of the characteristics that all myeloid cell types share is their high phenotypic plasticity. This plasticity translates into the ability to respond to different signals, acquiring particular phenotypes, ultimately promoting (or resolving) pathophysiological conditions. Closely related with this feature, recently, the trained immunity concept emerged, highlighting that myeloid cell are capable of acquire immunological memory.
A deep understanding of the molecular pathways that drive myeloid cells reprogramming, a detailed description and identification of the myeloid subsets in oncologic, infectious, autoimmune and metabolic disease as well as it association with patients clinical outcome are essential for the development of new therapeutic approaches. Integrating the previously mentioned with trained immunology concepts open the possibility for the development of next generation immunotherapies. The ultimate goal of this collection is to provide an integration of these data to assess if there are myeloid cells profiles associated with disease onset and development and identify its translational value.
We welcome Original Research, Reviews and Mini-reviews covering:
- Novel macrophages/ neutrophil/ monocytes subsets described in the context of disease.
- Molecular pathways involved in reprogramming (receptors, ligands, transcription factors of relevance).
- Strategies for the application of trained immunity approaches ( potential therapeutic approaches)
Myeloid cells constitute a fundamental part of the innate immune system, including many subsets with diverse functions. One of the characteristics that all myeloid cell types share is their high phenotypic plasticity. This plasticity translates into the ability to respond to different signals, acquiring particular phenotypes, ultimately promoting (or resolving) pathophysiological conditions. Closely related with this feature, recently, the trained immunity concept emerged, highlighting that myeloid cell are capable of acquire immunological memory.
A deep understanding of the molecular pathways that drive myeloid cells reprogramming, a detailed description and identification of the myeloid subsets in oncologic, infectious, autoimmune and metabolic disease as well as it association with patients clinical outcome are essential for the development of new therapeutic approaches. Integrating the previously mentioned with trained immunology concepts open the possibility for the development of next generation immunotherapies. The ultimate goal of this collection is to provide an integration of these data to assess if there are myeloid cells profiles associated with disease onset and development and identify its translational value.
We welcome Original Research, Reviews and Mini-reviews covering:
- Novel macrophages/ neutrophil/ monocytes subsets described in the context of disease.
- Molecular pathways involved in reprogramming (receptors, ligands, transcription factors of relevance).
- Strategies for the application of trained immunity approaches ( potential therapeutic approaches)
